Early Treatment Diabetic Retinopathy Study

Early Treatment Diabetic Retinopathy Study

The Early Treatment Diabetic Retinopathy Study was a landmark multicenter randomized clinical trial that evaluated interventions to prevent vision loss in patients with diabetic retinopathy. The trial, conducted under the auspices of the National Institutes of Health and primarily supported by the National Eye Institute, compared laser photocoagulation strategies and adjunctive therapies, producing data that influenced practice across ophthalmology, endocrinology, and public health. The study's methods and long-term follow-up informed guidelines adopted by organizations such as the American Academy of Ophthalmology and the World Health Organization.

Background

Development of the study arose amid rising prevalence estimates from the Framingham Heart Study era and growing clinical concern voiced by clinicians at institutions like Johns Hopkins Hospital, Massachusetts General Hospital, and Mayo Clinic. Investigators drew on randomized trial methodology from trials such as Diabetes Control and Complications Trial and historical laser research at centers including Bascom Palmer Eye Institute and Wills Eye Hospital. Funding and oversight involved collaborations among the National Eye Institute, academic medical centers, and regulatory bodies such as the Food and Drug Administration. Key advisory figures came from professional societies like the American Diabetes Association, the American Academy of Ophthalmology, and the Association for Research in Vision and Ophthalmology.

Study Design and Methods

The trial enrolled participants with diabetic retinopathy identified through metabolic care networks linked to clinics at University of Pennsylvania, University of Michigan, and University of California, San Francisco. The randomized design compared focal/grid photocoagulation and deferral strategies, plus evaluation of scatter (panretinal) photocoagulation for proliferative disease, alongside ancillary questions such as effects of moderate-dose aspirin versus placebo. Visual acuity testing employed protocols standardized similarly to methods used in multicenter trials like the Systolic Hypertension in the Elderly Program. Imaging included seven-field stereoscopic fundus photography techniques refined from work at The Moorfields Eye Hospital and grading performed at a central reading center modeled on infrastructures used by the Women's Health Initiative. Statistical oversight referenced analysis approaches from the International Clinical Trials Registry Platform era, with prespecified endpoints including doubling of visual-angle loss and progression to severe vision impairment.

Key Findings and Outcomes

The trial demonstrated that focal/grid photocoagulation reduced the risk of moderate vision loss among patients with clinically significant macular edema, while scatter photocoagulation reduced severe vision loss from proliferative diabetic retinopathy. These results led to quantifiable reductions in rates of vision loss similar in magnitude to benefits reported in contemporaneous studies like the Diabetic Retinopathy Study. Secondary analyses addressed the lack of benefit for aspirin in preventing retinal outcomes, echoing null findings from cardiovascular trials such as the Antiplatelet Trialists' Collaboration. Outcomes were disseminated through presentations at venues like the American Diabetes Association Scientific Sessions, publications in journals paralleling the influence of The New England Journal of Medicine and The Lancet, and guideline discussions in forums convened by the World Health Organization and Centers for Disease Control and Prevention.

Clinical Impact and Guidelines

Findings from the trial were rapidly integrated into clinical practice guidelines issued by the American Academy of Ophthalmology and influenced screening and treatment pathways across tertiary centers including Mount Sinai Hospital and Cleveland Clinic. Laser photocoagulation protocols derived from the study became standard of care in ophthalmology departments at institutions such as Columbia University Irving Medical Center and Stanford Health Care, and informed training curricula at schools like Harvard Medical School and Johns Hopkins School of Medicine. Public health programs coordinated by entities such as the Centers for Disease Control and Prevention and national diabetes programs referenced the trial when developing screening recommendations and resource allocation, and professional organizations including the Royal College of Ophthalmologists considered the evidence in international guideline harmonization.

Subsequent Research and Long-term Follow-up

Long-term follow-up studies and ancillary investigations drew on cohorts and methods from the original trial and intersected with research programs at centers like Massachusetts Eye and Ear, Scheie Eye Institute, and Kellogg Eye Center. Later randomized and observational studies comparing focal photocoagulation with therapies developed subsequently, notably intravitreal pharmacotherapies pioneered at institutions such as Bascom Palmer Eye Institute and Wills Eye Hospital, referenced ETDRS endpoints to establish noninferiority and efficacy. Longitudinal data contributed to meta-analyses coordinated by consortia including the Cochrane Collaboration and informed revisions to recommendations by the American Diabetes Association and European Society of Retina Specialists. Epidemiologic linkage with diabetes outcome datasets from registries similar to those maintained by National Diabetes Services Scheme and national health systems enabled assessment of population-level impact on vision-related quality of life.

Category:Clinical trials Category:Ophthalmology Category:Diabetes mellitus